+

WO2001051644A3 - ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN - Google Patents

ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN Download PDF

Info

Publication number
WO2001051644A3
WO2001051644A3 PCT/DE2001/000130 DE0100130W WO0151644A3 WO 2001051644 A3 WO2001051644 A3 WO 2001051644A3 DE 0100130 W DE0100130 W DE 0100130W WO 0151644 A3 WO0151644 A3 WO 0151644A3
Authority
WO
WIPO (PCT)
Prior art keywords
domain
human
antibody
domains
dna sequences
Prior art date
Application number
PCT/DE2001/000130
Other languages
English (en)
French (fr)
Other versions
WO2001051644A2 (de
Inventor
Ingrid Choi
Melvyn Little
Inger Sandlie
Original Assignee
Deutsches Krebsforsch
Ingrid Choi
Melvyn Little
Inger Sandlie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Ingrid Choi, Melvyn Little, Inger Sandlie filed Critical Deutsches Krebsforsch
Priority to US10/181,305 priority Critical patent/US20040175786A1/en
Priority to EP01911351A priority patent/EP1250443A2/de
Publication of WO2001051644A2 publication Critical patent/WO2001051644A2/de
Publication of WO2001051644A3 publication Critical patent/WO2001051644A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Beschrieben wird ein Einzelketten-Antikörper, der dadurch gekennzeichnet ist, dass er (a) eine an humanes CD3 spezifisch bindende variable Domäne (scFv) enthält, und (b) seine konstanten Domänen von einem humanen IgM-Molekül stammen und die Cν3-Domäne und Cν4-Domäne, jedoch nicht die Cν1-Domäne und Cν2-Domäne umfassen. In einer bevorzugten Ausführungsform enthält der erfindungsgemässe Antikörper eine humane IgG3-Gelenkregion zwischen der variablen und konstanten Domäne. Beschrieben werden ausserdem diesen Antikörper codierende DNA-Sequenzen und diese DNA-Sequenzen enthaltende Expressionsvektoren und schliesslich die vorstehenden Verbindungen enthaltende Arzeimittel, vorzugsweise zur Prävention akuter Abstossungsreaktionen nach Organtransplantation.
PCT/DE2001/000130 2000-01-14 2001-01-10 ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN WO2001051644A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/181,305 US20040175786A1 (en) 2000-01-14 2001-01-10 Anti-cd3 single-chain antibodies having human cmu3 and cmu4 domains
EP01911351A EP1250443A2 (de) 2000-01-14 2001-01-10 ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN C $g(m)?3- und C $g(m)?4- DOMÄNEN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10001372.4 2000-01-14
DE10001372A DE10001372A1 (de) 2000-01-14 2000-01-14 Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen

Publications (2)

Publication Number Publication Date
WO2001051644A2 WO2001051644A2 (de) 2001-07-19
WO2001051644A3 true WO2001051644A3 (de) 2001-12-06

Family

ID=7627538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/000130 WO2001051644A2 (de) 2000-01-14 2001-01-10 ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN

Country Status (4)

Country Link
US (1) US20040175786A1 (de)
EP (1) EP1250443A2 (de)
DE (1) DE10001372A1 (de)
WO (1) WO2001051644A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
US8952134B2 (en) 2011-09-26 2015-02-10 Jn Biosciences Llc Hybrid constant regions
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
WO2015132364A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024013401A1 (en) 2022-07-15 2024-01-18 Gadeta B.V. Novel method for identifying gamma t-cell (or delta t-cell) receptor chains (or gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024100136A1 (en) 2022-11-08 2024-05-16 Gadeta B.V. Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A. PLÜCKTHUN ET AL.: "New protein engineering approaches to multivalent and bispecific antibody fragments.", IMMUNOTECHNOLOGY, vol. 3, no. 2, June 1997 (1997-06-01), Amsterdam, die Niederlande, pages 83 - 105, XP004126672 *
H. CHEN: "Single-chain antibody (scFVOKT3)-induced T leukemia cell apoptosis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 38, March 1997 (1997-03-01), VSA, pages 31, XP002170003 *
I. CHOI ET AL.: "Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 1, January 2001 (2001-01-01), Weinheim, Deutschland, pages 94 - 106, XP001002634 *
L. NORDERHAUG ET AL.: "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 204, no. 1, 12 May 1997 (1997-05-12), Amsterdam, die Niederlande, pages 77 - 87, XP004061470 *
R. SMITH ET AL.: "Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.", THE JOURNAL OF IMMUNOLOGY, vol. 154, no. 5, 1 March 1995 (1995-03-01), Baltimore; MD, VSA, pages 2226 - 2236, XP002170004 *
S. HU ET AL.: "Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.", CANCER RESEARCH, vol. 56, no. 13, 1 July 1996 (1996-07-01), Baltimore, MD, VSA, pages 3055 - 3061, XP000645454 *
S. MA ET AL.: "Expression and characterization of a divalent chimeric anti-human CD3 single-chain antibody.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 43, no. 2, February 1996 (1996-02-01), Oxford, Grossbritannien, pages 134 - 139, XP002083387 *
T. OLAFSEN ET AL.: "IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells.", IMMUNOTECHNOLOGY, vol. 4, no. 2, October 1998 (1998-10-01), Amsterdam, die Niederlande, pages 141 - 153, XP004153638 *
V. SÖRENSEN ET AL.: "Effect of the IgM and IgA secretory tailpieces on polymerization and secretion of IgM and IgG.", THE JOURNAL OF IMMUNOLOGY, vol. 156, no. 8, 15 April 1996 (1996-04-15), Baltimore, MD, VSA, pages 2858 - 2865, XP002170005 *

Also Published As

Publication number Publication date
EP1250443A2 (de) 2002-10-23
WO2001051644A2 (de) 2001-07-19
US20040175786A1 (en) 2004-09-09
DE10001372A1 (de) 2001-08-02

Similar Documents

Publication Publication Date Title
WO2001051644A3 (de) ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
WO1994029451A3 (en) Humanised antibodies
WO2003034903A3 (en) Psma antibodies and protein multimers
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
WO2003004648A1 (fr) Anticorps bispecifique anticancer de l'ovaire humain-anti cd3
UA106036C2 (uk) Анти-мезотелінове антитіло та його застосування
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
GEP20074222B (en) Antibodies to cd40
WO2002002773A3 (en) Dual specificity antibodies and methods of making and using
CA2068222A1 (en) Monoclonal antibodies
WO2002032375A8 (en) Uses of monoclonal antibody 8h9
WO2002015846A3 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ATE370235T1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
WO2003010201A3 (en) Blood group antigen fusion polypeptides and methods of use thereof
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE370163T1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
WO2002094194A3 (en) Compositions and methods for inhibiting metastasis
DE50104015D1 (de) Verfahren zur selektiven bestimmung von blockierenden autoantikörpern gegen den tsh-rezeptor
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
WO2002074797A3 (en) Protein having multiple antigen/epitope sequences and being immobilized for the diagnosis of hiv infections
WO2002094376A3 (en) Compositions and methods for promoting or inhibiting ndpk

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2001911351

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001911351

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10181305

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001911351

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载